Differential effects of ibogaine on local cerebral glucose utilization in drug-naive and morphine-dependent rats

Brain Research

Volumn 1003, Issue 1-2, 2004, Pages 159-167

  Levant, Beth ^a   Pazdernik, Thomas L ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

14C 2 Deoxyglucose; Drug addiction; Drugs of abuse: opioids and others; Ibogaine; Local cerebral glucose utilization; Morphine; Neural basis of behavior

Indexed keywords

DEOXYGLUCOSE; IBOGAINE; PSYCHEDELIC AGENT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CEREBELLUM; CEREBELLUM FLOCCULUS; CINGULATE GYRUS; CONTROLLED STUDY; GLUCOSE UTILIZATION; HEMISPHERE; ISOTOPE LABELING; LOCUS CERULEUS; MALE; MORPHINE ADDICTION; NONHUMAN; NUCLEUS ACCUMBENS; OCCIPITAL CORTEX; PARIETAL LOBE; PREOPTIC AREA; PRIORITY JOURNAL; RAT;

ANIMALS; CEREBRAL CORTEX; GLUCOSE; IBOGAINE; MALE; MORPHINE DEPENDENCE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 1542298850     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2003.12.032     Document Type: Article

References (57)

1. Aghajanian G.K. LSD and phenethylamine hallucinogens: common sites of neuronal action. Pletscher A., Ladewig D. Fifty Years of LSD. 1994;27-41 The Parthanon Publishing Group, New York.
2. Alper K.R., Lotsof H.S., Frenken G.M., Luciano D.J., Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am. J. Addict. 8:1999;234-242.
3. 14C]2- deoxyglucose in cat. Exp. Brain Res. 42:1981;371-382.
4. Beck T., Wenzel J., Kushinsky K., Krieglstein J. Morphine-induced alteration of local cerebral glucose utilization in the basal ganglia. Brain Res. 497:1989;205-213.
5. Carpenter T.L., Pazdernik T.L., Levant B. Differences in quinpirole-induced local cerebral glucose utilization between naive and sensitized rats. Brain Res. 964:2003;295-301.
6. Childress A.R., Mozley P.D., McElgin W., Fitzgerald J., Reivich M., O'Brien C.P. Limbic activation during cue-induced cocaine craving. Am. J. Psychiatry. 156:1999;11-18.
7. Clow D.W., Lee S.J., Hammer R.P. Jr. Competitive (AP7) and non-competitive (MK-801) NMDA receptor antagonists differentially alter glucose utilization in rat cortex. Synapse. 7:1991;260-268.
8. Cohen S.R., Kimes A.S., London E.D. Morphine decreased cerebral glucose utilization in limbic and forebrain regions while pain has no effect. Neuropharmacology. 30:1991;125-134.
9. Daglish M.R., Weinstein A., Malizia A.L., Wilson S., Melichar J.K., Britten S., Brewer C., Lingford Hughes A., Myles J.S., Grasby P., Nutt D.J. Changes in regional cerebral blood flow elicited by craving memories in abstinent opiate-dependent subjects. Am. J. Psychiatry. 158:2001;1680-1686.
10. Dworkin S.I., Gleeson S., Meloni D., Koves T.R., Martin T.J. Effects of ibogaine on responding maintained by food, cocaine and heroin reinforcement in rats. Psychopharmacol. Berl. 117:1995;257-261.
11. Dzoljic E.D., Kaplan C.D., Dzoljic M.R. Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats. Arch. Int. Pharmacodyn. Ther. 294:1988;64-70.
12. Glick S.D., Kuehne M.E., Raucci J., Wilson T.E., Larson D., Keller R.W. Jr., Carlson J.N. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res. 657:1994;14-22.
13. Glick S.D., Maisonneuve I.M. Mechanisms of antiaddictive actions of ibogaine. Ann. N.Y. Acad. Sci. 844:1998;214-226.
14. Glick S.D., Maisonneuve I.M., Szumlinski K.K. Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. Alkaloids, Chem. Biol. 56:2001;39-53.
15. Glick S.D., Rossman K., Rao N.C., Maisonneuve I.M., Carlson J.N. Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology. 31:1992;497-500.
16. Glick S.D., Rossman K., Steindorf S., Maisonneuve I.M., Carlson J.N. Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur. J. Pharmacol. 195:1991;341-345.
17. Glick S.D., Rossman K., Wang S., Dong N., Keller R.W. Jr. Local effects of ibogaine on extracellular levels of dopamine and its metabolites in nucleus accumbens and striatum: interactions with D-amphetamine. Brain Res. 628:1993;201-208.
18. Goldman H., Fischer R., Nicolov N., Murphy S. Lysergic acid dydiethylamide affects blood flow to specific areas of the conscious rat brain. Experimentia. 31:1975;328-330.
19. Grant S., London E.D., Newlin D.B., Villemagne V.L., Liu X., Contoreggi C., Phillips R.L., Kimes A.S., Margolin A. Activation of memory circuits during cue-elicited cocaine craving. Proc. Natl. Acad. Sci. U. S. A. 93:1996;12040-12045.
20. Grome J.J., Harper A.M. Local cerebral glucose utilisation following indolamine- and piperazine-containing 5-hydroxytryptamine agonists. J. Neurochem. 46:1986;117-124.
21. 2A component of the ibogaine-induced discriminative stimulus. Pharmacol. Biochem. Behav. 59:1998;419-425.
22. Helsley S., Fiorella D., Rabin R.A., Winter J.C. A comparison of N,N-dimethyltryptamine, harmaline, and selected congeners in rats trained with LSD as a discriminative stimulus. Prog. Neuro-psychopharmacol. Biol. Psychiatry. 649:1998;649-663.
23. Helsley S., Rabin R.A., Winter J.C. Further investigations of the serotonergic properties of the ibogaine-induced discriminative stimulus. Prog. Neuro-psychopharmacol. Biol. Psychiatry. 23:1999;317-326.
24. Iadecola C., Nakai M., Mraovitch S., Ruggiero D.A., Tucker L.W., Reis D.J. Global increase in cerebral metabolism and blood flow produced by focal electrical stimulation of dorsal medullary reticular formation in rat. Brain Res. 272:1983;101-114.
25. Kilts C.D., Schweitzer J.B., Quinn C.K., Gross R.E., Faber T.L., Muhammad F., Ely T.D., Hoffman J.M., Drexler K.P. Neural activity related to drug craving in cocaine addiction. Arch. Gen. Psychiatry. 58:2001;334-341.
26. Kimes A.S., London E.D. Glucose utilization in the rat brain during chronic morphine treatment and naloxone-precipitated morphine withdrawal. J. Pharmacol. Exp. Ther. 248:1989;538-545.
27. Kraus M.A., Piper J.M., Kornetsky C. Persistent increases in basal cerebral metabolic activity induced by morphine sensitization. Pharmacol. Biochem. Behav. 57:1997;89-100.
28. Kurumaji A., Nehls D.G., Park C.K., McCulloch J. Effects of NMDA antagonists, MK-801 and CPP, upon local cerebral glucose use. Brain Res. 496:1989;268-284.
29. Lotsof H.S. Rapid Method for Interrupting the Narcotic Addiction Syndrome. 1985;. U.S. Patent 4,499,096.
30. Lotsof H.S. Rapid Method for Interrupting the Cocaine and Amphetamine Abuse Syndrome. 1986;. U.S. Patent 4,587,243.
31. Lotsof H.S. Rapid Method for Interrupting or Attenuating the Nicotine/Tobacco Dependency Syndrome. 1991;. U.S. Patent 5,026,697.
32. Lotsof H.S. Ibogaine in the treatment of chemical dependency disorders: clinical perspectives. Multidiscip. Assoc. Stud. 5:1995;16-27.
33. Luciano D. Observations on treatment with ibogaine [letter]. Am. J. Addict. 7:1998;89-90.
34. Maisonneuve I.M., Rossman K.L., Keller R.W. Jr., Glick S.D. Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats. Brain Res. 575:1992;69-73.
35. Mraovitch S., Calando Y., Onteniente B., Peschanski M., Seylaz J. Cerebrovascular and metabolic uncoupling in the caudate-putamen following unilateral lesion of the mesencephalic dopaminergic neurons in the rat. Neurosci. Lett. 157:1993;140-144.
36. Naranjo C. Psychotherapeutic possibilities of new fantasy-enhancing drugs. Clin. Toxicol. 2:1969;209-224.
37. 35S]GTPgammaS binding. NeuroReport. 9:1998;109-114.
38. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2 ed. 1986;Academic Press, Sydney.
39. Pearl S.M., Hough L.B., Boyd D.L., Glick S.D. Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism. Pharmacol. Biochem. Behav. 57:1997;809-815.
40. Pearl S.M., Maisonneuve I.M., Glick S.D. Prior morphine exposure enhances ibogaine antagonism of morphine-induced dopamine release in rats. Neuropharmacology. 35:1996;1779-1784.
41. Pope H.G.J. Tabernanthe iboga: an African narcotic plant of social importance. Econ. Bot. 23:1969;174-184.
42. Popik P. Facilitation of memory retrieval by the "anti- addictive" alkaloid, ibogaine. Life Sci. 59:1996;Pl379-Pl385.
43. Popik P., Layer R.T., Skolnick P. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol. Rev. 47:1995;235-253.
44. Rabin R.A., Winter J.C. Ibogaine and noribogaine potentiate the inhibition of adenylyl cyclase activity by opioid and 5-HT receptors. Eur. J. Pharmacol. 316:1996;343-348.
45. Sershen H., Hashim A., Lajtha A. Characterization of multiple sites of action of ibogaine. Alkaloids, Chem. Biol. 56:2001;115-133.
46. Sheppard S.G. A preliminary investigation of ibogaine: case reports and recommendations for further study. J. Subst. Abuse Treat. 11:1994;379-385.
47. Sisko B. Interrupting drug dependence with ibogaine: a summary of four case histories. Multidiscip. Assoc. Stud. 4:1993;15-24.
48. Skolnick P. Ibogaine as a glutamate antagonist: relevance to its putative antiaddictive properties. Alkaloids, Chem. Biol. 56:2001;55-62.
49. Sokoloff L. The relationship between function and energy metabolism: its use in the localization of functional activity in the nervous system. Neurosci. Res. Prog. Bull. 19:1981;159-210.
50. 14C)deoxyglucose method for the measurement of the local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized rat. J. Neurochem. 28:1977;897-916.
51. Volkow N.D., Fowler J.S., Wolf A.P., Hitzemann R., Dewey S., Bendriem B., Alpert R., Hoff A. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am. J. Psychiatry. 148:1991;621-626.
52. Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 16:1997;357-372.
53. Wan R.Q., Cheng A.W., Mattson M.P. Intermittant fasting reduced glucose uptake in the brain. Soc. Neurosci. Abst. 33:2003;112-193.
54. Waxman S.G. Clinical Neuroanatomy. 2003;McGraw-Hill, New York.
55. Wei D., Maisonneuve I.M., Kuehne M.E., Glick S.D. Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats. Brain Res. 800:1998;260-268.
56. Windh R.T., Little P.J., Kuhn C.M. The ontogeny of mu opiate tolerance and dependence in the rat: antinociceptive and biochemical studies. J. Pharmacol. Exp. Ther. 273:1995;1361-1374.
57. Wooten G.F., DiStephano P., Collins R.C. Regional cerebral glucose utilization during morphine withdrawal in the rat. Proc. Natl. Acad. Sci. U. S. A. 79:1982;3360-3364.